Patient interest & the evolving role of adjunctive support in Rheumatoid Arthritis
Current research indicates growing patient and clinician interest in integrative, functional medicine approaches to rheumatoid arthritis (RA). Many individuals with RA explore supportive strategies alongside conventional disease-modifying antirheumatic drugs (DMARDs). Physical therapy, rehabilitation, and nutrition-focused interventions are frequently incorporated to improve function and quality of life (Aletaha & Smolen, 2018). Within this framework, the paracrine activity of mesenchymal stem cells (MSCs) has emerged as a subject of preclinical investigation — not as a primary treatment, but as a potential adjunctive avenue to modulate inflammatory processes. This educational article summarizes peer-reviewed literature on MSC-derived paracrine signaling in the context of inflammatory arthritis.
Umbilical cord MSCs within an integral medicine framework
Umbilical cord-derived MSCs (UC-MSCs) possess distinctive immunomodulatory properties, including the secretion of anti-inflammatory cytokines such as IL-10 and TGF-β (Wang et al., 2021). In preclinical models of RA, UC-MSC paracrine signaling has been observed to reduce pro-inflammatory Th17 cell responses and promote regulatory T-cell expansion. Within an integral functional medicine framework, UC-MSCs are considered an area of active research that may complement conventional rehabilitation, dietary modifications, and physical therapy. Current evidence suggests that UC-MSC secretome, particularly exosomes, may influence synovial macrophage polarization, though clinical translation remains in early phases (Cosenza et al., 2017).
Paracrine mechanisms: exosomes and synovial inflammation
Preclinical studies have evaluated MSC-derived exosomes as key mediators of paracrine signaling. In collagen-induced arthritis (CIA) models, administration of MSC exosomes is associated with reduced synovial hyperplasia, decreased inflammatory cell infiltration, and preservation of cartilage architecture (Zhang et al., 2021). Evidence suggests that exosomal miR‑146a and miR‑155 modulate NF‑κB signaling in synovial fibroblasts. These findings support the hypothesis that paracrine factors — rather than direct engraftment — drive most observed anti-inflammatory effects in inflammatory arthritis settings.
| Preclinical study (year) | Model / MSC type | Observed outcomes |
|---|---|---|
| Cosenza et al., 2017 | CIA mouse / BM-MSC exosomes | ↓ synovial inflammation, ↓ cartilage proteoglycan loss |
| Zhang et al., 2021 | Rat adjuvant arthritis / UC-MSC exosomes | ↓ joint swelling, ↓ serum TNF-α, IL-6 |
| Maumus et al., 2020 | CIA / Adipose MSC secretome | Reduced osteoclastogenesis, reduced bone erosion |
Limitations and adjunctive context
Despite encouraging preclinical findings, there is no approved MSC-based product for rheumatoid arthritis. All described strategies remain categorized as adjunctive and are not yet approved for clinical use. Variability in cell source, dosing, and potency assays limits cross-study comparisons. Regulatory agencies (FDA, EMA, COFEPRIS) require rigorous randomized controlled trials before clinical recommendation. This article summarizes research only; none of the described adjunctive strategies are approved for routine clinical care of RA.
1. Cosenza S, Ruiz M, Toupet K, Jorgensen C, Noël D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci Rep. 2017;7(1):16214.
2. Zhang J, Rong Y, Luo C, et al. Umbilical cord mesenchymal stem cell-derived exosomes alleviate rheumatoid arthritis by inhibiting the NF-κB signaling pathway. Stem Cells Int. 2021;2021:6652081.
3. Maumus M, Jorgensen C, Noël D. Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. Biochimie. 2020;179:144-152.
4. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-1372.